Cargando…
No arguments for extra risk from ibuprofen in SARS-COV2 infection
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836811/ https://www.ncbi.nlm.nih.gov/pubmed/32829912 http://dx.doi.org/10.1016/j.therap.2020.07.006 |
| _version_ | 1783642825487810560 |
|---|---|
| author | Moore, Nicholas |
| author_facet | Moore, Nicholas |
| author_sort | Moore, Nicholas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7836811 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78368112021-01-26 No arguments for extra risk from ibuprofen in SARS-COV2 infection Moore, Nicholas Therapie Letter to the Editor Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. 2020 2020-07-11 /pmc/articles/PMC7836811/ /pubmed/32829912 http://dx.doi.org/10.1016/j.therap.2020.07.006 Text en © 2020 Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Moore, Nicholas No arguments for extra risk from ibuprofen in SARS-COV2 infection |
| title | No arguments for extra risk from ibuprofen in SARS-COV2 infection |
| title_full | No arguments for extra risk from ibuprofen in SARS-COV2 infection |
| title_fullStr | No arguments for extra risk from ibuprofen in SARS-COV2 infection |
| title_full_unstemmed | No arguments for extra risk from ibuprofen in SARS-COV2 infection |
| title_short | No arguments for extra risk from ibuprofen in SARS-COV2 infection |
| title_sort | no arguments for extra risk from ibuprofen in sars-cov2 infection |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836811/ https://www.ncbi.nlm.nih.gov/pubmed/32829912 http://dx.doi.org/10.1016/j.therap.2020.07.006 |
| work_keys_str_mv | AT moorenicholas noargumentsforextrariskfromibuprofeninsarscov2infection |